BioNTech (NASDAQ:BNTX) Given “Buy” Rating at Jefferies Financial Group

Jefferies Financial Group reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a report published on Monday morning,MarketScreener reports.

BNTX has been the subject of a number of other reports. Cowen reiterated a “hold” rating on shares of BioNTech in a research report on Monday. Wells Fargo & Company set a $150.00 target price on BioNTech and gave the stock an “overweight” rating in a report on Tuesday, August 5th. Bank of America reduced their price target on shares of BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a report on Tuesday, October 14th. Finally, Morgan Stanley restated an “overweight” rating and issued a $134.00 target price on shares of BioNTech in a research note on Monday. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $134.17.

BioNTech Stock Down 0.9%

Shares of BNTX opened at $103.03 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. The company has a market capitalization of $23.20 billion, a P/E ratio of -64.66 and a beta of 1.45. The business’s 50 day simple moving average is $102.50 and its 200-day simple moving average is $105.01. BioNTech has a one year low of $81.20 and a one year high of $129.27.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same quarter last year, the business posted $0.81 earnings per share. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that BioNTech will post -3.88 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several hedge funds have recently bought and sold shares of the company. OneDigital Investment Advisors LLC acquired a new position in BioNTech during the first quarter worth approximately $288,000. Bank of New York Mellon Corp boosted its stake in BioNTech by 18,892.9% in the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company’s stock valued at $63,593,000 after purchasing an additional 694,691 shares during the period. LBP AM SA grew its holdings in BioNTech by 20.7% in the 1st quarter. LBP AM SA now owns 305,221 shares of the company’s stock valued at $27,793,000 after buying an additional 52,303 shares in the last quarter. Banque Pictet & Cie SA boosted its position in shares of BioNTech by 165.7% in the first quarter. Banque Pictet & Cie SA now owns 5,499 shares of the company’s stock valued at $501,000 after acquiring an additional 3,429 shares during the period. Finally, Cerity Partners LLC acquired a new position in shares of BioNTech in the first quarter valued at about $357,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.